Compounds > rutundic acid
Page last updated: 2024-11-12

rutundic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

rutundic acid: isolated from the leaves of Hex pupurea; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12315075
CHEMBL ID1271052
CHEBI ID70684
SCHEMBL ID1045049
MeSH IDM0465572

Synonyms (23)

Synonym
CHEMBL1271052 ,
chebi:70684 ,
rotundic acid
(3beta,4alpha)-3,19,23-trihydroxyurs-12-en-28-oic acid
20137-37-5
urs-12-en-28-oic acid, 3,19,23-trihydroxy-, (3beta,4alpha)-
bdbm50391059
S9514 ,
SCHEMBL1045049
rutundic acid
DTXSID80173963
AKOS032949054
Q27139015
(1r,2r,4as,6ar,6as,6br,8ar,9r,10s,12ar,14bs)-1,10-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
mfcd13186912
i1exo1ic acid
CS-0019536
HY-N2217
22-deoxyilexolic acid a
3ss,19a,23-trihydroxyurs-12-en-28-oic acid
MS-29090
(1r,2r,4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-1,10-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicene-4a(2h)-carboxylic acid
A879816

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Although many studies about the total saponins have been reported, the absorption triterpenoids and pharmacokinetic behaviors were unclear."( Rapid profiling and pharmacokinetic studies of multiple potential bioactive triterpenoids in rat plasma using UPLC/Q-TOF-MS/MS after oral administration of Ilicis Rotundae Cortex extract.
Jin, J; Li, H; Liu, Z; Ruan, Q; Tong, Y; Xuan, S; Yang, B; Zhao, Z, 2018)		0.48
" In this study, we evaluated the pharmacokinetic interactions of rotundic acid with pedunculoside and other ingredients from Ilicis Rotundae Cortex with rotundic acid and pedunculoside, and preliminarily investigated the effects of gut microbiota on their pharmacokinetics using a pseudo-germ-free rat model."( Effects of Gut Microbiota and Ingredient-Ingredient Interaction on the Pharmacokinetic Properties of Rotundic Acid and Pedunculoside.
Chen, X; Cui, H; Jin, J; Li, H; Liu, Z; Ruan, Q; Xuan, S; Yang, B; Zhao, Z, 2019)		0.51
"These findings indicated that verapamil could significantly affect the pharmacokinetic profiles of RA in rats."( Influence of verapamil on the pharmacokinetics of rotundic acid in rats and its potential mechanism.
Ci, X; Gu, Y; Liu, C; Ma, H; Shang, H; Si, D; Sun, Y; Wang, Z, 2021)		0.62

Bioavailability

ExcerptReferenceRelevance
" The poor bioavailability limits its further development and potential clinic application."( Influence of verapamil on the pharmacokinetics of rotundic acid in rats and its potential mechanism.
Ci, X; Gu, Y; Liu, C; Ma, H; Shang, H; Si, D; Sun, Y; Wang, Z, 2021)		0.62
" It was demonstrated that P-gp and CYP3A were involved in the transport and metabolism of RA, which might contribute to the low oral bioavailability of RA."( Influence of verapamil on the pharmacokinetics of rotundic acid in rats and its potential mechanism.
Ci, X; Gu, Y; Liu, C; Ma, H; Shang, H; Si, D; Sun, Y; Wang, Z, 2021)		0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
triterpenoidAny terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)20.10000.00053.49849.7600AID683328
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1668310Inhibition of LPS-induced TNF-alpha production in human BV2 cells at 250 ug/ml preincubated for 4 hrs followed by LPS stimulation and measured after 24 hrs by ELISA2020Bioorganic & medicinal chemistry letters, 06-15, Volume: 30, Issue:12
Betulin isolated from Pyrola incarnata Fisch. inhibited lipopolysaccharide (LPS)-induced neuroinflammation with the guidance of computer-aided drug design.
AID745203Cytotoxicity against human SPC-A1 cells after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Design, synthesis and cytotoxicity of cell death mechanism of rotundic acid derivatives.
AID745200Cytotoxicity against human HeLa cells after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Design, synthesis and cytotoxicity of cell death mechanism of rotundic acid derivatives.
AID745199Cytotoxicity against human NCI-H446 cells after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Design, synthesis and cytotoxicity of cell death mechanism of rotundic acid derivatives.
AID527185Cytotoxicity against human fibroblast cells at 10 uM after 48 hrs2010Journal of natural products, Oct-22, Volume: 73, Issue:10
Cytotoxic Hexacyclic Triterpene Acids from Euscaphis japonica.
AID745201Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Design, synthesis and cytotoxicity of cell death mechanism of rotundic acid derivatives.
AID527184Cytotoxicity against human CEM cells at 10 uM after 48 hrs2010Journal of natural products, Oct-22, Volume: 73, Issue:10
Cytotoxic Hexacyclic Triterpene Acids from Euscaphis japonica.
AID745202Cytotoxicity against human A375 cells after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Design, synthesis and cytotoxicity of cell death mechanism of rotundic acid derivatives.
AID527181Cytotoxicity against human MCF7 cells at 10 uM after 48 hrs2010Journal of natural products, Oct-22, Volume: 73, Issue:10
Cytotoxic Hexacyclic Triterpene Acids from Euscaphis japonica.
AID527182Cytotoxicity against human NCI-H460 cells at 10 uM after 48 hrs2010Journal of natural products, Oct-22, Volume: 73, Issue:10
Cytotoxic Hexacyclic Triterpene Acids from Euscaphis japonica.
AID1668306Cytotoxicity against human BV2 cells assessed as survival rate at 250 ug/ml2020Bioorganic & medicinal chemistry letters, 06-15, Volume: 30, Issue:12
Betulin isolated from Pyrola incarnata Fisch. inhibited lipopolysaccharide (LPS)-induced neuroinflammation with the guidance of computer-aided drug design.
AID527183Cytotoxicity against human HT-29 cells at 10 uM after 48 hrs2010Journal of natural products, Oct-22, Volume: 73, Issue:10
Cytotoxic Hexacyclic Triterpene Acids from Euscaphis japonica.
AID683328Inhibition of human recombinant PTP1B using p-nitrophenyl phosphate as substrate assessed as p-nitrophenol release after 30 mins2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Rhododendric acid A, a new ursane-type PTP1B inhibitor from the endangered plant Rhododendron brachycarpum G. Don.
AID1436764Anticomplement activity in New Zealand White rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway preincubated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 min2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Anticomplement triterpenoids from the roots of Ilex asprella.
AID1668311Inhibition of LPS-induced IL-1beta production in human BV2 cells at 250 ug/ml preincubated for 4 hrs followed by LPS stimulation and measured after 24 hrs by ELISA2020Bioorganic & medicinal chemistry letters, 06-15, Volume: 30, Issue:12
Betulin isolated from Pyrola incarnata Fisch. inhibited lipopolysaccharide (LPS)-induced neuroinflammation with the guidance of computer-aided drug design.
AID1436763Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway preincubated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometer2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Anticomplement triterpenoids from the roots of Ilex asprella.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (4.17)29.6817
2010's15 (62.50)24.3611
2020's8 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		2.3110aromatic ether;
nitrile;
polyether;
tertiary amino compound
donepezil
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.		2.2510aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent
ursolic acid
[no description available]		2.8330hydroxy monocarboxylic acid;
pentacyclic triterpenoid		geroprotector;
plant metabolite
betulin
betulin: isolated from various white birch bark (BETULA). betulin : A pentacyclic triterpenoid that is lupane having a double bond at position 20(29) as well as 3beta-hydroxy and 28-hydroxymethyl substituents.		2.2510diol;
pentacyclic triterpenoid		analgesic;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
metabolite
Tormentic acid
tormentic acid: aglycone of Rosamultin		2.0510triterpenoidmetabolite
fibrinogen
Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.		2.1110iditolfungal metabolite
pomolic acid
pomolic acid: from Rosa woodsii & Hyptis capitata; structure in first source		2.4920triterpenoidmetabolite
euscaphic acid
euscaphic acid: isolated from medicinal plant, Euscaphis japonica Pax.; structure; RN given refers to 2alpha,3alpha-isomer. euscaphic acid : A pentacyclic triterpenoid that is urs-12-en-28-oic acid substituted by hydroxy groups at positions 2, 3 and 19 respectively (the 2alpha,3alpha-stereoisomer). It has been isolated from the leaves of Rosa laevigata.		2.0510hydroxy monocarboxylic acid;
pentacyclic triterpenoid;
triol		plant metabolite
lutein
Lutein: A xanthophyll found in the major LIGHT-HARVESTING PROTEIN COMPLEXES of plants. Dietary lutein accumulates in the MACULA LUTEA.. xanthophyll : A subclass of carotenoids consisting of the oxygenated carotenes.		2.2110carotenolfood colouring;
plant metabolite
beta-escin
[no description available]		2.4620
madecassic acid
[no description available]		2.1110
corosolic acid
[no description available]		2.4720triterpenoidmetabolite
ilekudinol b
ilekudinol B: stimulates glucose uptake; from Weigela subsessilis; structure in first source		2.1510
23-hydroxyursolic acid
23-hydroxyursolic acid: from medicinal plants of the Rubiaceae family; structure in first source. 23-hydroxyursolic acid : A pentacyclic triterpenoid that is ursolic acid substituted by an additional hydroxy group at position 23. It has been isolated from Lagerstroemia speciosa and Juglans sinensis.		2.5120dihydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite
pedunculoside
pedunculoside: from leaves of Ilex chinensis; structure given in first source		2.7830
ilexgenin a
ilexgenin A: extract from the leaves of the plant		2.1710
rk 682
[no description available]		2.0710
ziyuglycoside i
ziyuglycoside I: isolated from the leaves of Hex pupurea; structure in first source		2.4620
ziyuglycoside ii
ziyuglycoside II: isolated from Sanguisorba officinalis; structure in first source		2.1510
ConditionIndicatedRelationship StrengthStudiesTrials
Extravascular Hemolysis
[description not available]		02.1510
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		02.1510
Innate Inflammatory Response
[description not available]		02.7620
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.7620
Lipid Metabolism Disorders
Pathological conditions resulting from abnormal anabolism or catabolism of lipids in the body.		02.610
Fatty Liver, Nonalcoholic
[description not available]		02.8220
Non-alcoholic Fatty Liver Disease
Fatty liver finding without excessive ALCOHOL CONSUMPTION.		02.8220
Alloxan Diabetes
[description not available]		02.5520
Diabetes Mellitus, Adult-Onset
[description not available]		02.2110
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.2110
Lung Injury, Acute
[description not available]		02.3110
Acute Lung Injury
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).		02.3110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.3110
Breast Cancer
[description not available]		02.1710
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.1710
Benign Neoplasms
[description not available]		02.4920
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.4920
Carcinoma, Small Cell Lung
[description not available]		02.1310
Adenocarcinoma, Basal Cell
[description not available]		02.1310
Cancer of Lung
[description not available]		02.1310
Malignant Melanoma
[description not available]		02.1310
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.1310
Lung Neoplasms
Tumors or cancer of the LUNG.		02.1310
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.1310
Small Cell Lung Carcinoma
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).		02.1310